2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2301

Trend of Osteoporosis and Osteoporotic Fragility Fractures Among Select Autoimmune Rheumatologic Diseases: Results from National Inpatient Sample

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2443

Trends in the Incidence of Lymphomas and Leukemias in Patients with Rheumatoid Arthritis in Spain: An Observational Cohort Study of Hospital Discharges from 1999 to 2015

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2666

Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2395

Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2684

Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2530

Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2362

Understanding Patients’ Perceptions of Gout

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2547

Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2254

Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2218

Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2545

Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2189

Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2371

Use of Social Media Among Patients with Rheumatic Diseases

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2213

Usefulness of Shoulder Radiographs to Aid in Determining Need for Advanced Imaging to Detect Operable or Inoperable Full-Thickness Rotator Cuff Tears

Imaging of Rheumatic Diseases Poster III: Other Modalities

9:00AM-11:00AM: Abstract Number: 2192

User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)

Health Services Research Poster III – ACR/ARHP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].